Genentech
Richard Scheller is executive vice president, Research and Early Development at Genentech. In this role, he is responsible for overseeing the strategy for Genentech's research, drug discovery, business development and early development activities (through proof of concept in the clinic). Scheller also serves on Genentech's Research Review Committee. Scheller is a member of Genentech's executive committee and the Enlarged Roche Corporate Executive Committee.
Scheller joined Genentech in 2001 as senior vice president, Research, and was promoted to executive vice president, Research in 2003, and appointed chief scientific officer in June 2008. He assumed his current role in May 2009. Prior to joining Genentech, Scheller was appointed to the position of professor of Molecular and Cellular Physiology and Biological Sciences in 1993 and as an investigator with the Howard Hughes Medical Institute in 1994. Scheller received his first academic appointment to Stanford University in 1982.
Scheller's work has earned him numerous awards, including the 1997 National Academy of Sciences Award in Molecular Biology and the 2010 Kavli Prize in Neuroscience. He is a member of the Academy of Arts and Sciences and the National Academy of Sciences, and has served on numerous advisory boards, including the National Advisory Mental Health Council of the National Institutes of Health. He has published more than 200 papers in peer-reviewed scientific journals.
Scheller received his Bachelor of Science in biochemistry at the University of Wisconsin, Madison and was awarded his doctorate in chemistry from the California Institute of Technology, where he was also a postdoctoral fellow, Division of Biology. Scheller was also a postdoctoral fellow at Columbia University, College of Physicians & Surgeons.
Related Links: www.gene.com
Last Updated: Mon, Apr 18, 2011
| Category | Title | Author/Speaker | Organization | Length | Date |
|---|---|---|---|---|---|
| Video | Choose Your Words Carefully | Richard Scheller | Genentech | 03:18 | 04/2011 |
| Podcast | Developing Products that Save Lives | Richard Scheller | Genentech | 01:00:29 | 04/2011 |
| Video | Developing Products that Save Lives [Entire Talk] | Richard Scheller | Genentech | 59:37 | 04/2011 |
| Video | Drug Development Process | Richard Scheller | Genentech | 05:06 | 04/2011 |
| Video | Encouraging Innovation and Risk Taking | Richard Scheller | Genentech | 02:51 | 04/2011 |
| Video | Ethical Issues in Drug Development | Richard Scheller | Genentech | 04:40 | 04/2011 |
| Video | Motivating a Biotechnology Workforce | Richard Scheller | Genentech | 04:41 | 04/2011 |
| Video | Moving From Academia to Industry | Richard Scheller | Genentech | 05:05 | 04/2011 |
| Video | Pharmaceutical Market Realities | Richard Scheller | Genentech | 03:26 | 04/2011 |
| Video | Startup Opportunities in Biotechnology | Richard Scheller | Genentech | 03:36 | 04/2011 |
Genentech Executive Vice President Richard Scheller describes his early days in management. Lacking knowledge of many business practices and operations, Scheller worked to bring himself up to speed, particularly in the area of managing and working with employees. In this amusing video, Scheller says these experiences taught him that managers must choose their words carefully, because employees will ultimately try to do what you ask.
As Genentech's Executive Vice President of Research and Early Development, Richard Scheller leads scientists discovering medicines that will significantly impact the lives of patients. In this candid interview, he describes the challenges of his industry, and outlines the required steps for developing products in a heavily regulated environment. Scheller also shares some personal learning curves faced when he elected to leave academic life for a new role in a commercial enterprise.
As Genentech's Executive Vice President of Research and Early Development, Richard Scheller leads scientists discovering medicines that will significantly impact the lives of patients. In this candid interview, he describes the challenges of his industry, and outlines the required steps for developing products in a heavily regulated environment. Scheller also shares some personal learning curves faced when he elected to leave academic life for a new role in a commercial enterprise.
Richard Scheller lays out the complex steps involved in the early research and subsequent development of drug products. As Genentech's Executive Vice President of Research and Early Development, Scheller directs the early stages of the process before handing off produced molecules for further development by the company. Scheller admits that while research is his clear focus, he respects the incredible logistical challenges of trying to bring a product to market.
In this clip, STVP Executive Director Tina Seelig asks Genentech Executive Vice President Richard Scheller to explain how he encourages his team to innovate in the face of financial risks. As the head of Genentech's research and early development, Scheller accepts failure as part of the process. He also describes how the company mitigates risk by maintaining a balanced portfolio of products, with each drug in the portfolio measured by commercial value and probable technical success.
Genentech Executive Vice President Richard Scheller discusses some of the thought-provoking ethical issues that arise in the drug development process. To illuminate the issue, Scheller describes the painful challenges of the clinical trial placebo process, often required by the Food and Drug Administration. He also articulates some of the ethical implications related to drug costs and insurance reimbursements.
Genentech Executive Vice President Richard Scheller believes knowing their work truly impacts peoples' lives motivates his team. "The first thing is meaningful work," says Scheller. He also shares examples of real patient stories that were tremendously memorable, as well as some compensation strategies employed by the company.
Genentech Executive Vice President Richard Scheller articulates his thought process in deciding to leave a tenured faculty position to join a commercial enterprise. While leaving Stanford was hard to do, says Scheller, joining Genentech provided new intellectual challenges and opportunities to apply his biological insights to tackling diseases.
Genentech Executive Vice President Richard Scheller describes the hard financial realities of producing cutting-edge drugs for the developed world. Scheller states that it takes 15 years, on average, for a drug product to move from concept to sale. This fact, along with the company's large-scale financial investments, places tremendous pricing pressure on the finished product.
Richard Scheller, Genentech's Executive Vice President of Research and Early Development, believes it is unlikely, if not impossible, for small companies to push drug products through the final stage of development. However, Scheller also thinks a smart biotechnology startup could do early stage development and then turn to larger firms for product licensing or acquisition. Scheller also discusses the state of research and development at Genentech, in comparison to other firms.